Interleukin-36 plays a pivotal role in GPP pathogenesis by driving neutrophils and Th17 cells’ recruitment and activation within psoriatic lesions.[9] Spesolimab inhibits IL-36R, disrupting the inflammatory cascade mediated by IL-36α/γ cytokines. The gene discussed is IL36A; the disease is psoriasis 14, pustular.